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Abstract
Background: The treatment of human cancer has been seriously hampered for decades by resistance to
chemotherapeutic drugs. Mechanisms underlying this resistance are far from being entirely known. A very efficient
mechanism of tumor resistance to drugs is related to the modification of tumour microenvironment through
changes in the extracellular and intracellular pH. The acidification of tumor microenvironment depends on proton
pumps that actively pump protons outside the cells, mostly to avoid intracellular acidification. In fact, we have
shown in pre-clinical settings as pre-treatment with proton-pumps inhibitors (PPI) increase tumor cell and tumor
responsiveness to chemotherapeutics. In this study pet with spontaneously occurring cancer proven refractory to
conventional chemotherapy have been recruited in a compassionate study.
Methods: Thirty-four companion animals (27 dogs and 7 cats) were treated adding to their chemotherapy
protocols the pump inhibitor lansoprazole at high dose, as suggested by pre-clinical experiments. Their responses
have been compared to those of seventeen pets (10 dogs and 7 cats) whose owners did not pursue any other
therapy than continuing the currently ongoing chemotherapy protocols.
Results: The drug was overall well tolerated, with only four dogs experiencing side effects due to gastric
hypochlorhydria consisting with vomiting and or diarrhea. In terms of overall response twenty-three pets out of 34
had partial or complete responses (67.6%) the remaining patients experienced no response or progressive disease
however most owners reported improved quality of life in most of the non responders. On the other hand, only
three animals in the control group (17%) experienced short lived partial responses (1-3 months duration) while all
the others died of progressive disease within two months.
Conclusions: high dose proton pump inhibitors have been shown to induce reversal of tumor chemoresistance as
well as improvement of the quality of life in pets with down staged cancer and in the majority of the treated
animals PPI were well tolerated. Further studies are warranted to assess the efficacy of this strategy in patients with
advanced cancers in companion animals as well as in humans.
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Introduction
Cancer initiation, progression, and invasion occur in a
complex and dynamic microenvironment which depends
on the hosts and sites where tumors develop. The
response to chemotherapy by tumor cells depends on
the concentration of cytostatics accumulated within the
cells. The accumulation of anticancer drugs in tumor
cells is dependent on functional expression of efflux
transporters, but also on the pH of extracellular micro-
environment. However, while the role of chemotran-
sporters in the chemoresistance of malignant tumors
has been very well documented, little is known about
the role of tumor acidity and mechanisms underlying
tumor acidification, including proton exchangers and
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Tumor cells rely on H
+ exchangers to relieve themselves
from the dangerous protons byproduct of cancer meta-
bolism that could trigger a cascade of lytic enzymes that
ultimately would lead to self-digestion. Among these the
most prominent are the vacuolar H
+-ATPases (V-
ATPases). V-ATPases are ATP dependent H
+ transpor-
ters that utilize the energy freed by the hydrolysis of
ATP with the active transport of protons from the cyto-
plasm to the lumen of intracellular compartments or, if
located within the cytoplasmic membrane, the extracel-
lular compartment [1-4]. Two important physiological
mechanisms of regulating V-ATPase activity in vivo are
reversible dissociation of the domain carrying ATP from
the proton exchanger domain and changes in coupling
efficiency of proton transport and ATP hydrolysis
[5-12]. Malignant tumor cells overexpress lysosomal
proteins on the cell surface, with abnormal lysosomal
activities, possibly involving deranged V-ATPase func-
tion [13,14]. The acidic tumor environment is a conse-
quence of anaerobic glucose metabolism resulting in
accumulation of acid byproducts such as lactates. This
involves the upregulation of hypoxia-inducible factor 1a
[15] or can be dependent on inadequate tumor perfu-
sion, hypoxia secondary to disordered tumor growth or
enhanced transmembrane pH regulation [16]. These
pumps, coupled with other ion exchangers, play a para-
mount role in the establishment and maintenance of
malignant tumor microenvironment and their action
lead to the selection of more aggressive cell phenotypes
able to survive in this highly hostile microenvironment.
V-ATPases play a critical role in the maintenance of
an appropriate relatively neutral intracellular pH, and an
acidic extracellular pH by actively excreting protons
either through ion exchange mechanisms or by segregat-
ing H
+ within cytoplasmic organelles that are subse-
quently expelled [17]. It is hypothesized that the low
extracellular pH of tumors might trigger proteases
(MMP-2, MMP-9, cathepsin B, and cathepsin L), leading
to the dissolution of extracellular matrix. Proton
exchangers-mediated acidification of tumor microenvir-
onment significantly contributes to tumor invasion and
dissemination [18,19]. In fact, it has been shown that by
inhibiting V-ATPases through RNA interference, it was
possible to prevent cancer metastases in a murine
model [19]. This could be a novel strategy to deal with
the process of tumor dissemination through the increase
of the extracellular tumor pH, thus inhibiting the activa-
tion of tumor proteases. From the therapeutic point of
view, the changes in the pH gradient occurring between
the intracellular and the extracellular compartments as
well as the pH gradient between the cytoplasm and the
intracellular organelles can be significantly involved in
the mechanism of drug resistance [20-22]. There are
several proposed mechanisms involved in this phenom-
enon, including decreased uptake or neutralization of
weakly basic drugs by the acidic tumor microenviron-
ment or the confinement of chemotherapy drugs within
lysosomal vesicles [21-25]. An accelerated turnover of
acidic vesicles may represent an additional tumor strat-
egy of drug resistance based on counteracting current
transportation [26,27]. Interestingly, the expression of
proton pumps is increased in chemoresistant pheno-
types and is increased by anticancer drugs [28-31].
Investigation in xenograft models with different human
tumor histologies have shown as proton pump inhibi-
tion may on one hand induce chemosensibilization, on
the other hand trigger a clear tumor cytotoxicity [26,27].
Proton pump inhibitors aren o r m a l l ya d o p t e di nt h e
treatment of gastritis, Zollinger-Ellison syndrome and,
limitedly to veterinary oncology, gastric hyperacidity sec-
ondary to mast cell tumors in dogs and cats [32-36].
These drugs have been shown to be highly effective at
inhibiting V-ATPases in vitro and well tolerated and
extremely efficacious in murine models, resulting in
increased chemotherapy efficacy and improved tumor
control [27,31,37,38]. Moreover, according to data
reported in current veterinary literature, at least in two
dogs with gastrinoma, PPI therapy with omeprazole
resulted in survivals in excess of 2 years. Such long sur-
vivals, are potentially more due to tumor control sec-
ondary to cancer microenvironment manipulation than
to palliation of hyper acidic syndrome and prevention of
gastrointestinal ulcerations [33,35]. Aim of this study
was to investigate the feasibility, tolerability and efficacy
of high dose proton pump inhibitor lansoprazole as a
rescue to revert chemoresistance in companion animals
affected by neoplasms non responsive to anticancer
drugs.
Methods
Patient selection
Privately owned canine and feline patients with
advanced neoplasms that showed progression despite
chemotherapy were selected for the study. Upon tumor
escape from pharmaceutical control, owners were
offered three options: a) discontinuation of all thera-
pies, b) continuation of chemotherapy alone, c) conti-
nuation of chemotherapy with the addition of high
dose lansoprazole.
Previous informed consent was obtained from the
owners. In order to be enrolled in the study, according
to the Italian law (116/92) and the guidelines defined by
the ethical committee of the National Cancer Institute “
Regina Elena” of Rome, Italy, patients, staged according
to the World Health Organization (WHO) grading sys-
tem, were considered eligible if they fulfilled the follow-
ing criteria:
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nitrogen [BUN], creatinine, phosphorus, and urine spe-
cific gravity).
2 Absence of underlying life threatening diseases or
other medical complications (e.g. diabetes mellitus).
3 Compliance of the owner for follow-up rechecks.
4 A presumptive life expectancy of at least four weeks.
5 Overall performance status assessed according to the
modified Karnowsky system, had to be less than 3 (Table 1).
Staging process included a thorough anamnesis, physi-
cal examination, caliper or ultrasonographic measure-
ment of the neoplasm, complete blood cell count (CBC),
serum biochemistry profile, thoracic radiographs (three
projections: two laterals and one ventro-dorsal), and
abdominal ultrasonography. In order to confirm the
diagnoses, histological re-examination of the biopsies
were performed following standard protocols, using
Hematoxylin/Eosin and Hematoxylin/Van Gieson stain-
ings by one of the authors (AB).
Treatment
Twenty-seven privately owned dogs and seven cats pre-
sented to the Regina Elena Cancer Institute with clini-
cally chemoresistant neoplasms and were entered the
proton pump inhibitors arm in the modified phase I/II
study between September 2009 and April 2011. Simi-
larly, a group of seventeen pets whose owners declined
to enroll their pets in the study but chose to continue
standard chemotherapy was followed as control group.
Treatment protocol in the experimental arm consisted
with lansoprazolo at 5 mg/Kg SID for three consecutive
days, at the time of each chemotherapy administration, to
decrease tumor pH and increase response to therapy, fol-
lowed by four days at the dose of 1 mg/Kg SID to prevent
gastric hyperacidity rebound. This schedule has been cho-
sen on the basis of previous studies on rodents and based
on the currently ongoing clinical trials in humans [27].
Response to treatment in terms of toxicity and tumor
response were assessed prior each therapy. At that time
a physical exam and tumor measure were performed.
Moreover thoracic radiographs and abdominal ultraso-
nography were performed every two months to check
for tumor spread. Toxicity was defined as disease pro-
cesses that occurred secondary to therapy and accord-
ingly scored (table 2). In order to have the best
Table 1 Modified Kamofsky’s performance criteria
Grade Criteria
0 Fully active, performs at predisease level
1 Activity less than predisease level; able to function as acceptable pet
2 Severely compromised activity; ambulatory only to point of eating, sleeping, and consistently eliminating in acceptable areas.
3 Completely disabled; must be force fed; unable to defecate or urinate
in acceptable areas
4 Dead
Table 2 Modified Eastern Cooperative Oncology Group
evaluation
Toxicity/Grade
Signs
Duration
Hospitalization Days
00
11
2 2-3
3 4-5
4 ≥ 5
Neutropenia
0 ≤ 500 neutrophils/mL
1 1,500-2,500 neutrophils/mL
2 ≥ 2,500 neutrophils/mL
3 500-999 neutrophils/mL
4 1,000-1,499 neutrophils/mL
Anorexia
0 None
1 Inappetance
2 Anorexia ≤ 3 days duration
3 Anorexia > 3 days but < 5 days
4 Anorexia ≥ 5 days 10% weight loss
Vomiting
0 None
1 Nausea
2 Sporadic, self-limiting
3 1-5 episodes per day, < 2 days
4 6-10 episodes per day, hospitalized
Diarrhea
0 None
1 Soft stools, responds to dietary modification
2 1-4 watery stools per day, < 2 days
3 4-7 watery stools per day or > 2 days
4 > 7 watery stools per day or bloody,
hospitalized
Infection
0 None
1 No medication
2 Required medication
3 Debilitating
4 Threatening
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owners were sent home with a questionnaire to be com-
pleted in order to record possible gastrointestinal side
effects of the protocol (Table 3). Tumor response was
defined as follows:
Complete Remission (CR) - the disappearance of all
evidence of cancer in all sites for a defined period of
time.
Partial Remission (PR) - the decrease in size of all
tumors by 50% or greater as measured by the sum of
the product of two diameters of each tumor for a
defined period of time.
Stable Disease (SD) - the decrease of < 50% or an
increase of < 25% in the sum of the product of two dia-
meters for a defined period of time.
Progressive Disease (PD) - the increase of 25% or
more in the sum of the product of two diameters for a
defined period of time.
No evidence of disease - absence of tumor growth
(local recurrence or distant metastases) after PPI and
chemotherapy for a defined period of time.
Finally, the owners were questioned prior to each
therapy on the activity level, performance status and
food and water consumption of their animals. Treat-
ment were scheduled to be continued for six additional
months in lymphoma patients, upon achievement of
complete remission and for 3 additional months in
patients with solid tumors.
Results
Dogs
PPI COHORT: Twenty-seven dogs entered the study
over a 19 months period and their characteristics and
treatment protocols are summarized in tables 4, 5 and
6. There were 8 mixed breed dogs, 4 Boxers, 3 West
Highland White Terriers, and one each of the following
breeds: Great Dane, Bull Mastiff, Bull dog, Schnauzer,
Husky, Labrador, Rottweiler, German Shepherd, Argen-
t i n eD o g o ,S e t t e r ,P o o d l e ,a n dB e a g l e .T h e r ew e r e1 6
males and 11 females (all of them spayed). The age ran-
ged from 5 to 15 years with a mean a mode of 10 years.
There were eleven cases of lymphoma, three of osteosar-
coma, three of mammary carcinoma, two of bladder car-
cinoma, and finally, one each of the following: acute
lymphocytic leukemia, hemangiosarcoma, anal sac carci-
noma, melanoma, fibrosarcoma, oral squamous cell car-
cinoma, nasal carcinoma, mammary carcinosarcoma. All
the patients had previous treatment with chemotherapy:
lymphoma patients had been previously treated with
first and rescue protocols (Madison Wisconsin or COP
and upon failure, rescue with MOPP. Protocols details
are provided in tables 4 and 5). Upon failure they were
treated with reinstituted MOPP coupled with PPI. Only
exception a patient with cutaneous lymphoma who
developed intolerance to vincristine and, in considera-
tion of its reduced cardiac fraction shortening, was trea-
ted with the doxorubin analogue mitoxantrone, coupled
Table 3 Daily evaluation form sent home and made out by the owners
Vomiting
None 3 episodes per day 5 episodes per day > 5 episodes per day > 5 per day OR
OR OR OR days lasting > 4 days and
vomiting lasting 2 days vomiting lasting 4 days for > 4 days life threatening
Diarrhea
None 2 more stools 6 more stools > 6 more stools > 6 and life
than normal than normal than normal hospitalized
Nausea
None Appetite loss with Salivating or lip Salivation or lip Salivation/ lip
normal eating habits smacking for 12 hrs smacking for 24 hrs smacking > 24 h
Appetite
Normal With treats or diet Appetite loss for 3 days OR Appetite loss for 5 days OR Loss > 5 days
change, ate 100% With treats or diet With treats or diet OR
change, ate 50% of normal change, ate few bites No interest,
no appetite
Flatulence
Normal 1-2 episodes per day 2-4 episodes per day 4-6 episodes per day > 6 episodes per day
Activity
Normal Mild lethargy Moderate lethargy, difficulty Severe lethargy, only Unable to
with daily activities gets up to go outside rise on own
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with a variable number of cycles of platinum drugs and/
or anthracyclines (or their syn t h e t i ca n a l o g u em i t o x a n -
trone), were treated, upon tumor progression, with
mitoxantrone in association with PPI. The only excep-
tions were a patient affected by vesical transitional cell
carcinoma whose owners elected to be treated with pir-
oxicam alone, because of financial issues, and three dogs
with osteosarcoma whose tumor type is not responsive
to veterinary adopted chemotherapy regimens that were
treated with the calcifying agent clodronate. Upon fail-
ure, clodronate has been reinstituted with high dose
Table 4 Madison Wisconsin lymphoma protocol
Week 1: Vincristine 0.7 mg/m
2 IV
Asparaginase 400 IU/kg IM
Pre-med with chlorphenamine: small-medium 2.5-
5 mg IM; medium-large 5-10 mg IM
Prednisolone 2 mg/kg PO SID
Start antacids: zantac 2 mg/kg PO BID
antepsin < 20 kg 500 mg, > 20 kg 1-2 g PO TID
Week 2: Cyclophosphamide 250 mg/m
2 PO or IV (+ NaCl)
Prednisolone 1.5 mg/kg PO SID
Stop antacids: after week 2
Week 3: Vincristine 0.7 mg/m
2 IV
Prednisolone 1 mg/kg PO SID
Week 4: Doxorubicin 30 mg/m
2 IV (+ 0.9% NaCl)
Pre-med with chlorphenamine and
metoclopramide 0.5-1 mg/kg IM/SC)
Prednisolone 0.5 mg/kg PO SID
Week 6: Vincristine 0.7 mg/m
2 IV
Week 7: Cyclophosphamide 250 mg/m
2 PO or IV (+ NaCl)
Week 8: Vincristine 0.7 mg/m
2 IV
Week 9: Doxorubicin 30 mg/m
2 IV (+ 0.9% NaCl)
Pre-med with chlorphenamine + metoclopramide
Week 11: Vincristine 0.7 mg/m
2 IV
Week 13: Cyclophosphamide 250 mg/m
2 PO or IV (+ NaCl)
Week 15: Vincristine 0.7 mg/m
2 IV
Week 17: Doxorubicin 30 mg/m
2 IV (+ 0.9% NaCl)
Pre-med with chlorphenamine + metoclopramide
Week 19: Vincristine 0.7 mg/m
2 IV
Week 21: Cyclophosphamide 250 mg/m
2 PO or IV (+ NaCl)
Week 23: Vincristine 0.7 mg/m
2 IV
Week 25: Doxorubicin 30 mg/m
2 IV (+ 0.9% NaCl)
Pre-med with chlorphenamine + metoclopramide
BLOODS:
Haematology: prior to each dose
Urine:- Dipstick after every cyclophosphamide dose
- Full urinalysis after week 7
CARDIAC SCAN:
At time of: - First doxorubicin dose
- Last doxorubicin dose
- 3 months post protocol completion
REPEAT VISITS:
If in complete remission, checks should be made at months 1, 2, 3 and 6NOTES:
￿ For dogs < 10 Kg, use a 1 mg/Kg dose of doxorubicin.
￿ All treatment is discontinued after week 25 if in complete remission.
￿ If neutrophil count is < 3 × 10
9/L wait 5-7 days and repeat haematology before giving chemo.
￿ If sterile haemorrhagic cystitis occurs on cyclophosphamide, discontinue and substitute Chlorambucil (1.4 mg/kg PO) for subsequently scheduled
cyclophosphamide injections.
￿ You can administer L-asparaginase (400 IU/kg IM) with each vincristine injection until CR is achieved.
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cohort.
CONTROL COHORT: ten dogs were treated just with
conventional chemotherapy during the study and their
characteristics and therapies are summarized in table 7.
There were 3 mixed breed dogs and one each of the fol-
lowing breeds: Setter, Boxer, Labrador, German Shep-
herd, Argentine Dogo, West Higland White Terrier and
Rottweiler. Overall there were 5 lymphoma patients, one
with acute lymphocytic leukemia, one with cutaneous
carcinoma, one with liposarcoma and two affected by
mammary carcinoma. All failed their therapies at differ-
ent times but the owners elected to pursue additional
chemotherapies without chemosensitizers.
TOXICITY: Twenty-three dogs tolerated the dose of
lansoprazole without need of reduction or discontinua-
tion. Four dogs experienced grade 1 and two dogs had
grade 2 gastrointestinal toxicity (diarrhea) that was man-
aged with probiotics. Five dogs had flatulence (grade 1-
3). One dog had grade 3 vomiting that required lanso-
prazole dose reduction (from 5 to 3 mg/kg). Three dogs
h a dt ob ew i t h d r a w nd u et ol a n s o p r a z o l ei n t o l e r a n c e .
Hematological toxicity of chemotherapy was not wor-
sened by the addition of PPI, being limited to two epi-
sodes of grade 1 neutropenia and one case of grade 2
neutropenia that did not require treatment. Seven out of
ten controls experienced progressive anemia and neutro-
philia with left shift due to poor responses to therapy or
progressive disease.
EFFICACY: In terms of efficacy nineteen out of
twenty-eight dogs experienced various degrees of
response lasting from two to twelve months, these
responses were more evident in dogs affected by lym-
phoma (9 out 11). A paradigmatic example is shown in
Figure 1, depicting the complete regression of a necrotic
lymphomatous ulcer upon addition of PPI to the che-
motherapy regimen of a dog with refractory lymphoma.
In osteosarcoma patients the efficacy consisted in poten-
tiation of clodronate efficacy in dogs with progressive
disease that resulted in 2 partial responses. An addi-
tional benefit, beside the arrest of tumor progression
has been a significant improvement of their Karnofsky
performance status, chara c t e r i z e db yas i g n i f i c a n t
decrease of the pain perception shown by a better
weight bearing condition and weight gain. In dogs with
melanoma, carcinoma and sarcoma the addition of lan-
soprazole resulted in high response rates as shown by
table 6 with one melanoma patient that died of thoracic
lymphosarcoma while still in remission for the melano-
cytic tumor.
Besides the osteosarcoma patients, two other dogs
with advanced disease (one affected by acute lymphocy-
tic leukemia and one by lymphoma) with a poor Kar-
nofsky performance status, upon clinical response,
moved to a lower grade condition (one moved from
grade 3 to grade 1, the other from grade 2 to grade 1).
On the contrary, only two dogs in the control group
benefited from the continuation of chemotherapy,
experiencing short lived partial responses (complete
responses were not documented) while the others had
progressive disease that ultimately resulted in their
death. Upon questioning, all the owners reported a
decreased/poor quality of life for their pets.
Cats
PPI COHORT: Seven cats entered the study during the
enrollment period, their characteristics and treatment
schedules are summarized in table 8. All of them where
Domestic Short Hair cats, four were females and three
were males, age ranged from 7 to 12 years. Tumor types
included three oral squamous cell carcinomas, two lym-
phomas, one fibrosarcoma and one breast carcinoma
that failed chemotherapy or various combinations of
surgery and chemotherapy. Upon recurrence or progres-
sive disease, PPI inhibitor lansoprazole has been added
to the chemotherapy protocol.
CONTROL COHORT: Seven cats entered the study
during the enrollment period, their characteristics are
summarized in table 9. All but a Norwegian cat where
Domestic Short Hair cats, three were females and four
were males, age ranged from 5 to 13 years. All the own-
ers of these patients elected the continuation of che-
motherapy despite its declining efficacy.
TOXICITY: Regarding the cats, gastrointestinal side
effects were limited to mild anorexia in one cat while
they were not noted in the remaining six. Systemic toxy-
coses were limited to one cat that experienced a severe
neutropenia (grade 3) leading to infection (grade 3) that
required hospitalization and antibiotic therapy. Again,
the control group patients had a much worse tolerance
to the therapy due to progressive disease.
EFFICACY: Six cats benefited with variable degrees of
response from the therapy. Four cats showed tumor
response (2 CR, 2 PR ), two cats had stabilization of the
d i s e a s ea n do n ew a san o nr e s p o n d e r .T h ec o m p l e t e
responders were a cat with an aggressive lymphoma that
had spread to the pancreas, the other was a cat with
Table 5 MOPP lymphoma protocol
DAY DRUG DOSE
0 Mechlorethamine 3.0 mg/m
2
Vincristine 0.75 mg/m
2
Procarbazine 50 mg/m
2PO SIDx 14 days
Prednisone 30 mg/m
2PO SID × 14 days
7 Mechlorethamine 3.0 mg/m
2
Vincristine 0.75 mg/m
2
Repeat on day 28, complete blood cell count on days 0, 7, 28 etc.
Spugnini et al. Journal of Translational Medicine 2011, 9:221
http://www.translational-medicine.com/content/9/1/221
Page 6 of 12Table 6 Characteristics and outcome of canine patients treated with pump inhibitors and chemotherapy
PATIENT AGE TUMOR PREV. TREATMENT THERAPY OUTCOME (MONTHS)
GREAT DANE 10 SPLENIC
HSA
SURGERY
METRONOMIC
METRONOMIC CR 3
WHWT 8 LSA MADISON
MOPP
MOPP CR 12
BULL MAST. 11 ALL MADISON
MOPP
MOPP CR 3
WHWT 8 LSA MADISON
MOPP
MOPP CR 8
ROTTW. 6 LSA MADISON
MOPP
MOPP CR 3
BOXER 8 LSA MADISON
MOPP
MOPP CR 7
BOXER 9 LSA MADISON
MOPP
MOPP CR 5
DOGO 10 LSA MADISON
MOPP
MOPP PR 3
WHWT 10 LSA MADISON
MOPP
MOPP PD
BOXER 10 LSA COP
MOPP
MOPP CR5+
LABRADOR 8 LSA COP
MOPP
MOPP CR5+
BULL DOG 10 SKIN LSA MADISON
MOPP
MITOXANTRONE CR5+
POODLE 12 LSA COP
MOPP
MOPP DISCONTINUED
SETTER 14 ORAL SCC MITOXANTRONE MITOXANTRONE DISCONTINUED
MIXED 11 NASAL CA MITOXANTRONE MITOXANTRONE PR 3+
MIXED 10 OSA BIOPSY CLODRONATE PR 7
MIXED 11 OSA BIOPSY CLODRONATE PR 11
SCHNAUTZER 9 OSA BIOPSY CLODRONATE DISCONTINUED
MIXED 15 TCC
BLADDER
PIROXICAM PIROXICAM SD 7+
BEAGLE 12 TCC
BLADDER
SURGERY
MITOXANTRONE
MITOXANTRONE CR 2+
ROTTWEILER 5 MELANOMA SURGERY
CARBOPLATIN
CARBOPLATIN NED 5+
MIXED 10 MAMMARY
CA
SURGERY
MITOXANTRONE
MITOXANTRONE NED 5+
MIXED 10 MAMMARY
CA
CARBOPLATIN
DOXORUBICIN
MITOXANTRONE PR 9+
MIXED 11 FSA SURGERY, ECT MITOXANTRONE NED 3+
MIXED 12 MAMMARY
CA
SURGERY
MITOXANTRONE
MITOXANTRONE NED 4+
GERMAN 8 MAMMARY SURGERY MITOXANTRONE NED 4+
SHEPHERD CA MITOXANTRONE
HUSKY 13 MAMMARY SURGERY MITOXANTRONE NED 5+
CA.SA MITOXANTRONE
Abbreviations: ALL: acute lymphocytic leukemia; CA: carcinoma; CA.SA: carcinosarcoma; COP: cyclophosphamide, oncovin (vincristine), prednisone; ECT:
electrochemotherapy; FSA: fibrosarcoma; HSA: hemangiosarcoma; LSA: lymphosarcoma; MOPP: mechlorethamine, oncovin (vincristine), prednisone, procarbazine;
OSA: osteosarcoma; SCC: squamous cell carcinoma, WHWT: west highland white terrier. +: still alive.
Drugs schedule: doxorubicin 30 mg/m
2 every 21 days (pending hematological, cardiac and renal evaluation) up to 6 doses, carboplatin 300 mg/m
2 every 21 days,
mitoxantrone 6 mg/m
2 every 21 days. For Madison and MOPP protocols see table 4 and 5
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regression of the pancreatic dissemination in the lym-
phoma patients. The partial responders were a cat with
nasal lymphoma and a cat with mammary carcinoma.
Interestingly, the two cats with oral squamous cell carci-
noma that had stabilization of their disease showed a
significant improvement of their quality of life, in terms
of decreased bleeding, activity level, interaction with the
owners, improved grooming and increased appetite. In
terms of performance, they moved from a grade 3 to a
grade 1 Karnofsky status, mostly due to a significantly
decreased tumor induced pain. Again, the response rate
in the control group was much smaller with only two
control cats (one with a soft tissue sarcoma and the
other with lymphoma) experiencing a brief partial
response lasting two months during the therapy (see
Table 9).
At the time of writing a total of 15 patients (12 dogs
and 3 cats) are still alive and periodically monitored
leading to a survival rate of 44.4% and 42.8%, respec-
tively. Questioning the owners regarding their degree of
satisfaction with the outcomeo ft h et h e r a p yy i e l d e da
total of 85% of appreciation that ranged from “moder-
ate” to “enthusiastic”. The major cause of complain
being the gastrointestinal side effects (specifically the
flatulence) experienced by some dogs rather than the
degree of tumor response.
Discussion
From a strictly chemical evaluation of proton pump
inhibitors, it is conceivable that being pro-drugs needing
acidity to be transformed in the active drug [39], they
might be specifically active in the acidic tumor environ-
ments. Some reports inferred that metastatic tumors are
more acidic then primary tumors, but also that solid
tumors, either carcinoma or melanomas or sarcomas,
Table 7 Characteristics and outcome of canine patients treated with chemotherapy alone for refractory cancers
PATIENT AGE TUMOR PREV.
TREATMENT
THERAPY OUTCOME
(MONTHS)
MIXED 11 LSA MADISON +
MOPP
MADISON PD 1
SETTER 6 ALL MADISON +
MOPP
MADISON PD 1
BOXER 9 SKIN
CARCINOMA
DOXORUBICIN
CARBOPLATIN
CARBOPLATIN PR 2
WHWT 8 LSA MADISON +
MOPP
MADISON PR 1
ROTTW 7 LSA MADISON +
MOPP
MADISON PR 3
GERMAN 9 LSA MADISON +
MOPP
MADISON PD 1
SHEPHERD MOPP
LABRADOR 9 LSA MADISON +
MOPP
MOPP PD 2
MIXED 10 MAMMARY
CARCINOMA
DOXORUBICIN
CARBOPLATIN
DOXORUBICIN PR 1
DOGO 10 LIPOSARCOMA DOXORUBICIN
CARBOPLATIN
CARBOPLATIN PD 1
MIXED 10 MAMMARY
CARCINOMA
DOXORUBICIN
CARBOPLATIN
CARBOPLATIN PR 2
Abbreviations: ALL: acute lymphocytic leukemia; LSA: lymphosarcoma; MOPP: mechlorethamine, oncovin (vincristine), prednisone, procarbazine; WHWT: west
highland white terrier.
Drugs schedule: doxorubicin 30 mg/m
2 every 21 days (pending hematological, cardiac and renal evaluation) up to 6 doses, carboplatin 210 mg/m
2 every 21 days,
mitoxantrone 6 mg/m
2 every 21 days. For Madison and MOPP protocols see table 4 and 5.
Figure 1 Necrotized scrotal ulcer secondary to lymphosarcoma
infiltration in a bull dog at presentation (A & B) and after
initiation of rescue protocol (C & D).
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Page 8 of 12are more acidic than systemic tumors (i.e. leukemia)
[40]. Therefore, it can be speculated that proton pump
inhibitors might be more active against very malignant,
often entirely unresponsive to current therapies, tumors.
These observations are at least partially contradicted by
our findings since in both PPI cohorts we observed
extended responses ( > 6 months) in patients affected by
solid tumors as well as in patients with hematological
malignancies. In particular we found intriguing the con-
sistent responses obtained both in canine and feline
lymphoma patients that had shown a significant refrac-
toriness to standard multi-drug protocols. Pooling
together dogs and cats with lymphoma 8 patients out of
14 (57%) had responses in excess of 5 months. When
examining the outcome of patients with advanced solid
tumors, we observed a broad spectrum of tumors
Table 8 Characteristics and outcome of feline patients treated with pump inhibitors and chemotherapy
PATIENT AGE TUMOR PREV.
TREATMENT
THERAPY OUTCOME
(MONTHS)
DSH 10 BREAST
CARCINOMA
SURGERY
MITOXANTRONE
PD
MITOXANTRONE PR 4
DSH 12 ORAL SCC MITOXANTRONE
PD
MITOXANTRONE SD 2
DSH 10 ORAL SCC SURGERY
MITOXANTRONE
PD
MITOXANTRONE CR 5+
DSH 12 ORAL SCC BIOPSY
MITOXANTRONE
PD
MITOXANTRONE SD 6
DSH 12 LSA MOPP
× 3 months
MOPP CR 6+
DSH 8 NASAL LSA MOPP
PD
MOPP PR 3+
DSH 7 FSA SURGERY,
ECT × 2,
CARBOPLATIN
×2
MITOXANTRONE
×2
MITOXANTRONE PD
Abbreviations: DSH: domestic short hair; ECT: electrochemotherapy; FSA: fibrosarcoma; LSA: lymphosarcoma; MOPP: mechlorethamine, oncovin (vincristine),
prednisone, procarbazine; SCC: squamous cell carcinoma. +: still alive.
Drugs schedule: doxorubicin 30 mg/m
2 every 21 days (pending hematological, cardiac and renal evaluation) up to 6 doses, carboplatin 210 mg/m
2 every 21 days,
mitoxantrone 6 mg/m
2 every 21 days. For MOPP protocol see table 4 and 5.
Table 9 Characteristics and outcome of feline patients treated chemotherapy alone for chemoresistant cancers
PATIENT AGE TUMOR PREV.
TREATMENT
THERAPY OUTCOME
(MONTHS)
DSH 10 BREAST
CARCINOMA
DOXORUBICIN
CARBOPLATIN
CARBOPLATIN PD 1
DSH 12 FSA CARBOPLATIN CARBOPLATIN PR 2
DSH 10 ORAL SCC MITOXANTRONE
CARBOPLATIN
MITOXANTRONE PD 1
DSH 12 ORAL FSA DOXORUBICIN
CARBOPLATIN
CARBOPLATIN PD 1
DSH 12 LSA MADISON
MOPP
MOPP PR 2
DSH 7 FSA SURGERY,
DOXORUBICIN
CARBOPLATIN
CARBOPLATIN PD 1
NORVEGIAN 7 LSA MADISON
MOPP
MOPP PD 2
Abbreviations: DSH: domestic short hair; FSA: fibrosarcoma; LSA: lymphosarcoma; MOPP: mechlorethamine, oncovin (vincristine), prednisone, procarbazine; SCC:
squamous cell carcinoma. +: still alive.
Drugs schedule: doxorubicin 30 mg/m
2 every 21 days (pending hematological, cardiac and renal evaluation) up to 6 doses, carboplatin 210 mg/m
2 every 21 days,
mitoxantrone 6 mg/m
2 every 21 days. For Madison and MOPP protocols see table 4 and 5.
Spugnini et al. Journal of Translational Medicine 2011, 9:221
http://www.translational-medicine.com/content/9/1/221
Page 9 of 12vulnerable to our novel strategy. Among them, two of
our canine responders suffered neoplasms that are
usually refractory to current treatments, including a
spinal osteosarcoma and a metastatic anal sac carci-
noma. Sarcomas have been shown to be clearly acidic,
also by their ability to capture Acridine Orange [41-43].
However, also metastatic neoplasms are particularly
acidic as has been shown for human melanomas, that
thrive in particularly acidic microenvironments, as com-
pared to primary tumors [27]. In our study, the patient
affected by melanoma, showed responsiveness for the
treatment of gross disease, being consistent with the
observation that acidic condition increases susceptibility
of metastatic melanoma cells to proton pump inhibitors
[27]. We have showed a dramatic decrease of pain in
dogs with osteosarcoma andi nc a t sa f f e c t e db yo r a l
squamous cell carcinoma invading the maxilla or the
mandible, following clinical response to the treatment
with lansoprazole. This stabilization of tumor mass led
to palliation of bone cancer pain, resulting in improved
quality of life as shown by increased activity levels,
improved grooming and feeding ability, and weight gain,
as well. Modulation of tumor microenvironment pH
may be postulated for pain control as well [44], but it is
conceivable that a general acidosis is involved in
advanced cancer, contributing to the establishment of
the typical cachexia of cancer patients [45]. These data
are further substantiated by comparing the quality of life
of our PPI cohorts with that of controls that showed
progressive weight loss, decreased appetite, lower toler-
ance to chemotherapy (as shown by worse hematological
and gastrointestinal toxicities) and the general tendency
to move toward higher Karnowski levels. Bone cancer
induces bone lysis and remodeling leading to mechani-
cal bone deformation and inducing local tissue acidosis,
as well, which in turn may activate pain receptors
through several molecular mechanisms, particularly by
activation of the capsaicin receptor (transient receptor
potential vanilloid, TRPV1) [46,47]. Compelling evidence
has shown that TRPV1 is a crucial signal molecule in
the development of physiological and pathological pain
[46]. In fact, it has been shown that the reduction of pH
may induce both osteoclast-mediated bone reabsorption,
with direct stimulation of nociceptive receptors, and the
switch-on signal transmission by acid-sensing channels
such as TRPV 1 located on pain-sensing neurons
[46-48]. The high response rate observed in this study is
extremely promising, considering that most patients suf-
fered advanced cancers refractory to chemotherapy. This
PPI-induced response to anti-tumor therapy provides
the proof of concept that inhibition of the proton pump
may represent a new approach in the struggle against
cancer. The mechanisms of this efficacy lay in both the
improvement of chemotherapy by countering the acid
mileu of the tumors [26], but also the induction of
tumor self-digestion triggered by the increased cytoplas-
mic protonation [27-31].
Conclusions
The results obtained in pets with spontaneous neo-
plasms will be instrumental for the planning of further
investigations to be pursued in humans, thus hopefully
shortening the time frame necessary for the adoption of
this approach in clinical oncology [49,50]. Our data are
particularly comforting for patients with hematological
malignancies, due to the relatively high number of
enrolled canine and feline patients. The data on solid
tumors response, albeit promising need to be further
substantiated by the enrollment of other patients. Stu-
dies are currently ongoing for several specific solid
tumor histotypes that will be instrumental for the stan-
dardization of the PPI protocols.
Extending the number of patients treated with this
new approach is needed to further support the result of
this study and to identify both the more sensitive tumor
histotypes and the better PPI and conventional che-
motherapy combinations. Prospective studies will be
conducted to evaluate the efficacy of PPI administered
to non-chemoresistant tumors. Finally, we want to
emphasize that this study adds much on the set up of
new anti-tumor therapies based on drugs with low cost,
minimal toxicity, effective pain palliation and antitumor
efficacy.
List of abbreviations
PPI: proton pump inhibitors; TRPV1: transient receptor potential vanilloid.
Figure 2 Lymphosarcoma nodules in the pancreas of a cat,
diagnosed by fine needle aspiration with ultrasonographic
guidance. Ultrasonographic appearance of pancreatic lesions at
presentation (A & B) and after initiation of rescue protocol (C & D).
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